KLHL3: A Potential Drug Target and Biomarker (G26249)

Target Name: KLHL3

NCBI ID: G26249

KLHL3

KLHL3: A Potential Drug Target and Biomarker

Kelch-like family member 3 (KLHL3) is a protein that is expressed in various tissues of the human body, including the brain, heart, and skeletal muscles. Its function is not well understood, but it is known to be involved in the regulation of cell growth, differentiation, and survival.

Recent studies have suggested that KLHL3 may have potential as a drug target or biomarker. One possible mechanism by which KLHL3 could be targeted is through its role in the regulation of cell signaling pathways that are involved in various diseases, such as cancer, neurodegenerative diseases, and autoimmune disorders.

For example, KLHL3 has been shown to be involved in the regulation of the TGF-β pathway, a pathway that is involved in the development and maintenance of tissues, including organs and tissues. Studies have shown that KLHL3 can inhibit the activity of the TGF -尾 enzyme, which is involved in the regulation of cell growth and differentiation. This may have implications for the development of therapies that target TGF-β-related diseases.

Another potential mechanism by which KLHL3 could be used as a drug target is its role in the regulation of cell apoptosis, or programmed cell death.cell apoptosis. Apoptosis regulation is the normal process of cell death during the life cycle. Studies have found that KLHL3 can inhibit apoptosis, which provides new ideas for the treatment of apoptosis-related diseases.

Additionally, KLHL3 has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. This may have implications for the development of therapies that target cell-adhesion-related diseases.

As for biomarkers, KLHL3 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that it may be a useful biomarker for the diagnosis and treatment of these cancers. Additionally, KLHL3 has been shown to be involved in the regulation of stem cell proliferation, which may have implications for the development of therapies that target stem cell-related diseases.

Overall, KLHL3 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its function and the implications of its involvement in various biological processes.

Protein Name: Kelch Like Family Member 3

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that acts as a regulator of ion transport in the distal nephron (PubMed:14528312, PubMed:22406640, PubMed:23387299, PubMed:23453970, PubMed:23576762, PubMed:23665031). The BCR(KLHL3) complex acts by mediating ubiquitination of WNK4, an inhibitor of potassium channel KCNJ1, leading to WNK4 degradation (PubMed:23387299, PubMed:23453970, PubMed:23576762, PubMed:23665031). The BCR(KLHL3) complex also mediates ubiquitination and degradation of CLDN8, a tight-junction protein required for paracellular chloride transport in the kidney (By similarity)

The "KLHL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets